Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 36.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,262 shares of the biotechnology company’s stock after acquiring an additional 4,109 shares during the period. Vontobel Holding Ltd.’s holdings in Biogen were worth $2,334,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new stake in shares of Biogen in the 3rd quarter valued at about $33,000. Venturi Wealth Management LLC lifted its stake in Biogen by 73.8% in the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 93 shares during the last quarter. Itau Unibanco Holding S.A. boosted its holdings in shares of Biogen by 63.8% in the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 90 shares during the period. Golden State Wealth Management LLC purchased a new position in shares of Biogen during the fourth quarter worth approximately $41,000. Finally, Quent Capital LLC increased its holdings in shares of Biogen by 31.9% in the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 72 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BIIB shares. Oppenheimer cut their target price on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Jefferies Financial Group cut shares of Biogen from a “buy” rating to a “hold” rating and cut their target price for the company from $250.00 to $180.00 in a report on Monday, December 9th. Citigroup cut their target price on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a report on Thursday. Wolfe Research started coverage on shares of Biogen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Bank Of America (Bofa) cut their target price on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a report on Tuesday, February 11th. Seventeen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $211.96.

Biogen Price Performance

Biogen stock opened at $137.33 on Monday. Biogen Inc. has a 52 week low of $128.51 and a 52 week high of $238.00. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The firm’s 50-day simple moving average is $146.90 and its 200 day simple moving average is $172.99. The firm has a market capitalization of $20.01 billion, a PE ratio of 12.41, a P/E/G ratio of 1.65 and a beta of -0.08.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%. On average, equities research analysts predict that Biogen Inc. will post 16.42 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.